Publications

2016 Yildiz M, Brugger F, Kästle N, Tettenborn B. Neurocognitive impairment and corpus callosum atrophy in multiple sclerosis. Neurology, Psychiatry and Brain research. In Press. 2014 Yildiz M, Tettenborn B, Radue EW, Bendfeldt K, Borgwardt S. Association of cognitive impairment and lesion volumes in multiple sclerosis - A MRI study. Clin Neurol Neurosurg. 2014 Dec;127:54-8. doi: 10.1016/j.clineuro.2014.09.019. Epub 2014 Oct 14.

 

2014 Ulmer A, Dietz K, Hodak D, Polzer B, Scheitler S, Yildiz M, Schanz S, Röcken M, Garbe C, Breuninger H, Fierlbeck G, Klein CA: Quantitative measurement of melanoma spread in sentinel lymph nodes and survival. PLOS Medicine. IN PRESS

 

2013 Yildiz M, Tettenborn B, Borgwardt S. Trajectory of fatigue in natalizumab treated multiple sclerosis patients. Clinical Neurology and Neurosurgery.115 902– 903.

 

2012 Yildiz M. Slower Walking Speed Limits the Activities of Daily Living of Multiple Sclerosis Patients. International Journal of Clinical Practice. 2012 Nov; 66(11):1188-94.

 

2011 Yildiz M, Borgwardt S, Berger G. Parietal lobes in schizophrenia: Do they matter? Schizophrenia Research and Treatment. Volume 2011, Article ID 581686, doi:10.1155/2011/581686

 

2011 Haltmeier S, Yildiz M, Müller S, Anliker MD, Heinzerling L. Contact dermatitis induced by glatiramer acetate. Mult Scler. 2011 Nov;17(11):1390-2. Epub 2011 Jul 52011 Yildiz M, Tettenborn B. Fatigue und Multiple Sklerose. Info Neurologie&Psychiatrie 4/2011.

 

2011 Yildiz M, Tettenborn B, Putzki N: 25-hydroxyvitamin D Levels in Swiss Multiple Sclerosis Patients. Swiss Med Wkly. 2011; 141: w13192.

 

2011 Yildiz M, Tettenborn B, Putzki N: Multiple Sclerosis associated Fatigue during Disease Modifying Treatment with Natalizumab, Interferon-beta and Glatirameracetate. Eur Neurol

 

2011; 65: 231–232.2010 Yildiz M, Tettenborn B, Putzki N. Natalizumab and Beyond. Eur Neurol. 2010 Sep 4; 64(4): 236-240

 

2007 Yildiz M, Pflüger M, Riecher-Rössler A and Berger G: Aneurysms of pericallosal cerebral artery haemorrhage with consecutive psychosis. Australian and New Zealand Journal of Psychiatry 2007; 41(6): 554

 

2007 Berger G, Yildiz M, Aston J, Gschwandtner U, Riecher-Rössler A: Früherkennung psychotischer Störungen – ein praktischer Leitfaden. The Medical Journal 2007; 2: 29-32

 

2007 Yildiz M, Borgwardt S, Fusar-Poli P: Is a DNA sequence variation of the gene protocadherin Y a possible explanation for the six fold higher risk to develop schizophrenia in Moroccan males? Medical Hypotheses 2007; 69(3):694

 

2007 Yildiz M, Borgwardt S: Apoptosis may be the main cause for acceleration of normal changes in adolescent brain structure, leading to the onset of psychosis. Medical Hypotheses. 2008. 70(3): 706-7

Poster Presentations

2011 Yildiz M. Slower Walking Speed Limits the Activities of Daily Living of Multiple Sclerosis Patients. Submitted for European Neurological Society 21st Meeting 2011 in Lisbon, Portugal

 

2011 Calabrese P, Annoni JM, Baumann C, Baumann A, Haefeli T, Kamm C, Koch M, Yildiz M, Müri R: Screening for cognitive impairment in Multiple Sclerosis - Proposal of an expert-based two-step approach. 185th annual meeting of the Swiss Neurological Society 2011 in Lucerne, Switzerland

 

2011 Yildiz M, Tettenborn B, Putzki N: Multiple sclerosis associated fatigue during disease modifying treatment with natalizumab, interferon-beta and glatirameracetate: 1 year follow-up. American Academy of Neurology 63rd Annual Meeting 2011 in Honolulu, Hawaii, USA

 

2010 Yildiz M, Tettenborn B, Putzki N: Multiple Sclerosis associated Fatigue during Disease Modifying Treatment with Natalizumab, Interferon-beta and Glatirameracetate. Presentation in ECTRIMS 2010 in Goteborg, Sweden